FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)

View source ↗

Summary

FDA approved a supplemental NDA for the methylphenidate transdermal system, sponsored by PADAGIS US LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate Transdermal System (methylphenidate)

Snippet

SUPPL AP for METHYLPHENIDATE TRANSDERMAL SYSTEM (METHYLPHENIDATE)